European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs

by Marie Weil
October 13, 2022
A A
Share on LinkedinShare on Twitter

Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds 
 

DURHAM, N.C., and SAN DIEGO – October 12, 2022 – Tavros Therapeutics, Inc., a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities, and Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial five-year term.

Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for existing molecules.

Under the terms of the agreement, Tavros will receive $17.5 million in a cash upfront payment from Vividion, and is eligible to receive up to $430.5 million in potential future payments based on the achievement of prespecified preclinical, clinical development, and commercial milestones, as well as low-single-digit royalties on sales of certain potential programs. Vividion has options to pursue up to five additional targets with up to $482 million in potential additional future payments.

“The future of cancer treatment lies in the precision targeting of therapies in the optimal clinical settings. This partnership allows Tavros to expand the actionability of our platform into a new target space by pairing our precision oncology platform with Vividion’s unmatched ability to drug the traditionally undruggable,” said Tavros CEO and co-founder Eoin McDonnell, Ph.D. “We’re thrilled to launch our work with Vividion and harness our combined expertise to reach patients with difficult-to-treat cancers by uncovering and drugging the next generation of high-value targets and augmenting the efficacy of emerging compounds.”

“Despite decades of effort, many targets remain inaccessible to traditional small molecule drugs, and many others have uncertain relevance to disease,” said Vividion Therapeutics CEO Jeffrey Hatfield. “This collaboration brings together two orthogonal, highly innovative and synergistic approaches to drug discovery that will address both of these challenges. Vividion has the ability to find and drug previously unknown, or cryptic, functional binding pockets on oncology and immunology targets of high interest, while Tavros has the potential to uncover previously unknown synthetic vulnerabilities or dependencies in deadly tumor cells. We believe this powerful combination of leading-edge technologies has the potential to deliver multiple breakthrough discoveries for cancer patients in need.”

Tags: < Partnership

Related Industries

Health

Bayer and Hurdle launch precision health strategic partnership

December 1, 2023
Health

Bayer invests 130 million EUR in new production facility for innovative parenteral products

November 24, 2023
Health

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

November 23, 2023
Health

Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation

November 23, 2023
Health

Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany

November 18, 2023
Health

Marnix van Ginneken to succeed Ronald de Jong as Chairman of the Board of Philips Foundation

November 16, 2023

Petrobras signs an agreement with European Energy to assess the business opportunities for e-methanol

November 17, 2023

...

Mary Kay Expands To Hungary, Elevating Beauty and Empowerment in Central Europe

December 1, 2023

...

Petrobras renews partnership with one of Europe’s largest energy research institutes

November 17, 2023

...

vivo to Celebrate UEFA EURO 2024™ with Football Fans Around the World

November 14, 2023

...

AkzoNobel Powder Coatings partners with coatingAI to explore new frontiers in sustainability

December 6, 2023

...

Carlyle to invest in business software vendor GBTEC

November 24, 2023

...

DHL Express announces changes in leadership in Europe and the Americas

December 5, 2023

...

Volvo Cars appoints Helen Hu as General Counsel and Chief Legal Officer

December 7, 2023

...

DHL Supply Chain introduces Green Transport Policy to set a global sustainability standard for its transport fleet

November 16, 2023

...

DHL breaks ground on cutting-edge European Innovation Center in Germany, prioritizing holistic sustainability

November 30, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist